{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:49:35Z","timestamp":1780663775253,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:00:00Z","timestamp":1389139200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ijid.2013.04.005","type":"journal-article","created":{"date-parts":[[2013,6,3]],"date-time":"2013-06-03T23:46:03Z","timestamp":1370303163000},"page":"e966-e970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey"],"prefix":"10.1016","volume":"17","author":[{"given":"Tulin","family":"Demir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncay","family":"Buyukguclu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2013.04.005_bib0005","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.01760-09","article-title":"Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum beta-lactamase producing Escherichia coli","volume":"54","author":"Auer","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum beta lactamase producing Escherichia coli","volume":"168","author":"Bano","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijid.2013.04.005_bib0015","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkq051","article-title":"Fosfomycin susceptibility among extended-spectrum beta-lactamase producing Escherichia coli in Nottingham, UK","volume":"65","author":"Chislett","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jac\/dkn177","article-title":"Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?","volume":"62","author":"Knottnerus","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0025","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/jac\/dkq346","article-title":"Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase producing Escherichia coli","volume":"65","author":"Oteo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0924-8579(03)00231-0","article-title":"Why fosfomycin trometamol as first line therapy for uncomplicated UTI?","volume":"22","author":"Schito","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2013.04.005_bib0035","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","article-title":"Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0040","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2013.04.005_bib0045","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/dkg028","article-title":"An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOSENS Project","volume":"51","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0924-8579(03)00230-9","article-title":"In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance","volume":"2","author":"Marchese","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2013.04.005_bib0060","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug resistant (MDR) and extensively drug resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2013.04.005_bib0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended-spectrum beta-lactamase producing Escherichia coli related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2013.04.005_bib0070","series-title":"Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement M100-S21","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"10.1016\/j.ijid.2013.04.005_bib0075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000085625","article-title":"Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study","volume":"51","author":"Bonfiglio","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijid.2013.04.005_bib0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10156-010-0092-2","article-title":"Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women","volume":"17","author":"Matsumoto","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0085","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/jac\/dkh218","article-title":"In vitro susceptibility of recent antibiotic resistant urinary pathogens to ertapenem and 12 other antibiotics","volume":"53","author":"Alhambra","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0090","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dki344","article-title":"Risk factors for ciprofloxacin resistance among E. coli strains isolated from community-acquired urinary tract infections in Turkey","volume":"56","author":"Arslan","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0095","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1157\/13095372","article-title":"Activity of fosfomycin against extended-spectrum beta-lactamase producing E. coli and K. pneumoniae","volume":"24","author":"de Cueto","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijid.2013.04.005_bib0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/jinf.2002.1091","article-title":"A UK multicenter study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection","volume":"46","author":"Farrell","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2013.04.005_bib0105","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jmii.2010.08.012","article-title":"Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase producing E. coli and K. pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan","volume":"44","author":"Liu","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijid.2013.04.005_bib0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.diagmicrobio.2006.11.015","article-title":"In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta lactamase producing Escherichia coli isolated from urine and blood","volume":"58","author":"Ko","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2013.04.005_bib0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2013.04.005_bib0120","first-page":"25","article-title":"In vitro activity of fosfomycin against ESBL-producing Enterobacteriaceae of urinary origin","volume":"22","author":"Hernandez","year":"2009","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijid.2013.04.005_bib0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1413-8670(11)70151-9","article-title":"Fosfomycin in vitro resistance of E. coli from the community","volume":"15","author":"Biondo","year":"2011","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijid.2013.04.005_bib0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jac\/43.1.137","article-title":"Fosfomycin tromethamine susceptibility of outpatient urine isolates of E. coli and E. faecalis from ten North American medical centers by three methods","volume":"43","author":"Fuchs","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0135","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1128\/AAC.01834-09","article-title":"Prevalence of fosfomycin resistance among CTX-M producing Escherichia coli clinical isolates in Japan and identification of novel plasmid mediated fosfomycin modifying enzymes","volume":"54","author":"Wachino","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","article-title":"Extended-spectrum beta-lactamase producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy","volume":"39","author":"Meier","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2013.04.005_bib0145","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10156-010-0079-z","article-title":"A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections","volume":"16","author":"Ceran","year":"2010","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.medmal.2011.07.005","article-title":"Clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy","volume":"42","author":"Neuzillet","year":"2012","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijid.2013.04.005_bib0155","first-page":"211","article-title":"Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections","volume":"20","author":"Al\u00f3s","year":"2007","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijid.2013.04.005_bib0160","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1179\/joc.1997.9.6.394","article-title":"In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study","volume":"9","author":"Garcia-Rodriguez","year":"1997","journal-title":"J Chemother"},{"key":"10.1016\/j.ijid.2013.04.005_bib0165","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971213001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971213001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T14:54:38Z","timestamp":1539615278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971213001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1201971213001732"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2013.04.005","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2013.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}